<DOC>
	<DOCNO>NCT00956306</DOCNO>
	<brief_summary>This study design assess effect hepatic impairment pharmacokinetics , safety tolerability udenafil subject hepatic impairment compare healthy subject .</brief_summary>
	<brief_title>A Pharmacokinetic Study Udenafil Adult Subjects With Without Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Adult male age 20 64 year screen . 2 . Nonsmokers 3 . In case hepatic impair patient 4 . In case healthy volunteer , subject age ± 10 year old hepatic impair patient 5 . Subjects within ±20 % ideal body weight 6 . Subjects receive understood completely information regard current study give write informed consent voluntarily participate study follow instruction specify protocol . 1.History portosystemic shunt surgery .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Udenafil , DA-8159 , hepatic impairment , healthy volunteer</keyword>
</DOC>